Humira biosimilars finally launch on the US market

Three steps to drive meaningful change in quality control.

A selection of experts using genome editing and CRISPR/Cas9 for drug development purposes offer their views on the field.

Researchers have designed a “mini gene” therapy that could hold promise for treating Usher Syndrome Type 1F

Meet MAPSULES: metal iron-based nanocapsules that deliver targeted chemotherapy to solid tumors

How AI-based research tools can empower researchers and dive deeper into data

Sitting Down With… Sheila Mikhail, CEO and co-founder, AskBio; founder, Columbus Children’s Foundation.

PULSED – a self-sealing drug delivery depot – enables precise timing and tunable release of therapeutic doses

More pharma stakeholders are launching lawsuits over the US government’s Inflation Reduction Act.

Is safeguard sgRNA the key to reducing the off-target effects of gene editing, while increasing its potential applications?